Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
Gut|March 16, 2021
Blue poo: impact of gut transit time on the gut microbiome using a novel markerFrancesco Asnicar, Emily R Leeming, Eirini Dimidi, et al.Nature Communications|December 4, 2025
Faecal metabolites as a readout of habitual diet capture dietary interactions with the gut microbiomeRobert Pope, Alessia Visconti, Xinyuan Zhang, et al.Journal of the International Neuropsychological Society : JINS|December 5, 2009
An exploration of cognitive subgroups in Alzheimer's diseaseJulie E Davidson, Michael C Irizarry, Bethany C Bray, et al.Archives of Neurology|September 13, 2006
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutationsLianna Ishihara, Liling Warren, Rachel Gibson, et al.The American Journal of Clinical Nutrition|March 14, 2022
Blood pressure interactions with the DASH dietary pattern, sodium, and potassium: The International Study of Macro-/Micronutrients and Blood Pressure (INTERMAP)Queenie Chan, Gina M Wren, Chung-Ho E Lau, et al.Nature Food|April 28, 2023
Diet and lifestyle behaviour disruption related to the pandemic was varied and bidirectional among US and UK adults participating in the ZOE COVID StudyMohsen Mazidi, Emily R Leeming, Jordi Merino, et al.BMJ Open|May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' studyNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.BMJ Nutrition, Prevention & Health|July 26, 2021
Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study appPanayiotis Louca, Benjamin Murray, Kerstin Klaser, et al.Gut|September 7, 2021
Diet quality and risk and severity of COVID-19: a prospective cohort studyJordi Merino, Amit D Joshi, Long H Nguyen, et al.Lancet (London, England)|February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.Pageof 11